Loading
A phase 2 trial of limertinib and bevacizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. is a phase 2, randomised interventional study registered as NCT06982924 by Shanghai Chest Hospital, with a registry enrolment figure of 136 participants, started 2025-06-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: Limertinib+bevacizumab; Limertinib. Conditions listed: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer; PD-L1 Positive. Primary outcome: PFS. Lung eligibility wording from the registry: "Histologically or cytologically confirmed non - squamous non - small cell lung cancer (NSCLC)". No results are recorded here; the registry entry is the source.
Shares EGFR-mutated non-small-cell lung cancer, Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Innovent Biologics, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.